Pharma BD Deal Intelligence
Reckitt's 23.5% premium over Bayer's prior bid signals aggressive intent to anchor a US consumer-health platform; analysts cited Reckitt's Boots/Adams/SSL…
Reckitt Benckiser CEO Rakesh Kapoor: 'excited to enter the $30 billion global vitamins, minerals and supplements market with such a strong portfolio of high…
Reckitt Benckiser offered $42 per share ($1.4 billion), surpassing Bayer's prior $34 per share ($1.2 billion) bid, an $8-per-share premium, winning a bidding…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Reckitt Benckiser tendered $42/share (~$1.4B) for Schiff, 23.5% premium over Bayer's $34 bid. Schiff board signed merger agreement with Reckitt; Bayer declined to counterbid. Note: nutraceutical/consumer-health, borderline category.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. (this deal) | 2012 | $1.4B | 67 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2012 deals · Reckitt Benckiser plc deals · Other deals